帕博利珠单抗对比化疗二线或三线治疗转移性三阴性乳腺癌的III期试验
KEYNOTE-119是一项随机、开放标签、III期试验,比较帕博利珠单抗与研究者选择的化疗用于经治转移性三阴性乳腺癌。主要终点总生存期在PD-L1 CPS≥10、CPS≥1及总人群中均未显示帕博利珠单抗显著优于化疗。
要点
- 帕博利珠单抗对比化疗未显著改善经治转移性TNBC的总生存期。
- 帕博利珠单抗组3-4级治疗相关不良事件(如贫血、中性粒细胞减少)发生率低于化疗组。
核心结论
- 帕博利珠单抗对比研究者选择的化疗未显著改善经治转移性三阴性乳腺癌的总生存期。
研究设计与样本
- 随机、开放标签、III期试验,在31个国家150个中心进行,共622例患者随机1:1接受帕博利珠单抗200 mg每3周(312例)或研究者选择的单药化疗(310例)。
- 纳入标准:中心确认的转移性三阴性乳腺癌,ECOG PS 0-1,既往针对转移性疾病接受过1或2线系统治疗,最近治疗进展,且既往接受过蒽环类或紫杉类。
- 随机分层因素:PD-L1肿瘤状态(CPS≥1 vs <1)和既往新辅助/辅助治疗史 vs 初诊即转移。
- 主要终点:PD-L1 CPS≥10、CPS≥1及总人群的总生存期;仅在CPS≥1人群显示优效后才在总人群中检验优效性。
主要发现
- 最常见3-4级治疗相关不良事件:贫血(帕博利珠单抗组3例[1%] vs 化疗组10例[3%])、白细胞减少(1例[<1%] vs 14例[5%])、中性粒细胞计数减少(1例[<1%] vs 29例[10%])、中性粒细胞减少(0 vs 39例[13%])。
- 严重不良事件:帕博利珠单抗组61例(20%),化疗组58例(20%);治疗相关不良事件导致死亡:帕博利珠单抗组1例(<1%,循环衰竭),化疗组2例(1%,全血细胞减少和脓毒症1例,血胸1例)。
关键数值与推荐
- 帕博利珠单抗200 mg静脉注射,每3周一次,最多35个周期。
- 化疗选项:卡培他滨、艾日布林、吉西他滨或长春瑞滨,由研究者选择,每种药物入组上限60%。
- PD-L1阳性定义为CPS≥1,阴性为CPS<1;主要分析人群为CPS≥10、CPS≥1及总人群。
临床怎么用
- 帕博利珠单抗单药不推荐作为经治转移性三阴性乳腺癌的常规二线或三线治疗。
- 帕博利珠单抗的3-4级血液学不良事件发生率低于化疗,但严重不良事件比例两组相似(20% vs 20%)。
局限性
- 开放标签设计可能引入偏倚。
- 总生存未达到预设的统计学显著性,亚组分析为探索性。
- 研究仅纳入既往接受过1-2线系统治疗的患者,结果不能外推至其他治疗线数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pembrolizumab showed durable antitumour activity and manageable safety in metastatic triple-negative breast cancer in the single-arm KEYNOTE-012 and KEYNOTE-086 trials. In this study, we compared pembrolizumab with chemotherapy for second-line or third-line treatment of patients with metastatic triple-negative breast cancer. METHODS: KEYNOTE-119 was a randomised, open-label, phase 3 trial done at 150 medical centres (academic medical centres, community cancer centres, and community hospitals) in 31 countries. Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, who had received one or two previous systemic treatments for metastatic disease, had progression on their most recent therapy, and had previous treatment with an anthracycline or taxane were eligible. Patients were randomly assigned (1:1) using a block method (block size of four) and an interactive voice-response system with integrated web-response to receive intravenous pembrolizumab 200 mg once every 3 weeks for 35 cycles (pembrolizumab group), or to single-drug chemotherapy per investigator's choice of capecitabine, eribulin, gemcitabine, or vinorelbine (60% enrolment cap for each; chemotherapy group). Randomisation was stratified by PD-L1 tumour status (positive [combined positive score (CPS) ≥1] vs negative [CPS <1]) and history of previous neoadjuvant or adjuvant treatment versus de-novo metastatic disease at initial diagnosis. Primary endpoints were overall survival in participants with a PD-L1 combined positive score (CPS) of 10 or more, those with a CPS of 1 or more, and all participants; superiority of pembrolizumab versus chemotherapy was tested in all participants only if shown in those with a CPS of one or more. The primary endpoint was analysed in the intention-to-treat population; safety was analysed in the all-subjects-as-treated population. This Article describes the final analysis of the trial, which is now completed. This trial is registered with ClinicalTrials.gov, number NCT02555657. FINDINGS: From Nov 25, 2015, to April 11, 2017, 1098 participants were assessed for eligibility and 622 (57%) were randomly assigned to receive either pembrolizumab (312 [50%]) or chemotherapy (310 [50%]). Median study follow-up was 31·4 months (IQR 27·8-34·4) for the pembrolizumab group and 31·5 months (27·8-34·6) for the chemotherapy group. Median overall survival in patients with a PD-L1 CPS of 10 or more was 12·7 months (95% CI 9·9-16·3) for the pembrolizumab group and 11·6 months (8·3-13·7) for the chemotherapy group (hazard ratio [HR] 0·78 [95% CI 0·57-1·06]; log-rank p=0·057). In participants with a CPS of 1 or more, median overall survival was 10·7 months (9·3-12·5) for the pembrolizumab group and 10·2 months (7·9-12·6) for the chemotherapy group (HR 0·86 [95% CI 0·69-1·06]; log-rank p=0·073). In the overall population, median overall survival was 9·9 months (95% CI 8·3-11·4) for the pembrolizumab group and 10·8 months (9·1-12·6) for the chemotherapy group (HR 0·97 [95% CI 0·82-1·15]). The most common grade 3-4 treatment-related adverse events were anaemia (three [1%] patients in the pembrolizumab group vs ten [3%] in the chemotherapy group), decreased white blood cells (one [<1%] vs 14 [5%]), decreased neutrophil count (one [<1%] vs 29 [10%]), and neutropenia (0 vs 39 [13%]). 61 (20%) patients in the pembrolizumab group and 58 (20%) patients in the chemotherapy group had serious adverse events. Three (<1%) of 601 participants had treatment-related adverse events that led to death (one [<1%] in the pembrolizumab group due to circulatory collapse; two [1%] in the chemotherapy group, one [<1%] due to pancytopenia and sepsis and one [<1%] haemothorax). INTERPRETATION: Pembrolizumab did not significantly improve overall survival in patients with previously treated metastatic triple-negative breast cancer versus chemotherapy. These findings might inform future research of pembrolizumab monotherapy for selected subpopulations of patients, specifically those with PD-L1-enriched tumours, and inform a combinatorial approach for the treatment of patients with metastatic triple-negative breast cancer. FUNDING: Merck Sharp & Dohme.
引用
- Winer EP, Lipatov O, Im SA, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021. PMID: 33676601. doi:10.1016/S1470-2045(20)30754-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。